BioNTech And Oncoc4 Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival Versus Standard-Of-Care Chemotherapy In Previously Treated Squamous Non-Small Cell Lung Cancer Patients - BNTX News | Rallies
BioNTech And Oncoc4 Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival Versus Standard-Of-Care Chemotherapy In Previously Treated Squamous Non-Small Cell Lung Cancer Patients
BioNTech and OncoC4 presented updated data showing gotistobart nearly doubled median overall survival versus standard-of-care chemotherapy in previously treated squamous non-small cell lung cancer patients.
Gotistobart median overall survival was 18.5 months versus 10.0 months for chemotherapy in the phase 3 trial.
The pivotal stage 2 portion of PRESERVE-003 is currently ongoing at more than 160 sites globally.
BNTX•
